The Gut Microbiome in Atherosclerotic Cardiovascular Disease.
Zhuye Jie,Huihua Xia,Shi-Long Zhong,Qiang Feng,Shenghui Li,Suisha Liang,Huanzi Zhong,Zhipeng Liu,Yuan Gao,Hui Zhao,Dongya Zhang,Zheng Su,Zhiwei Fang,Zhou Lan,Junhua Li,Liang Xiao,Jun Li,Ruijun Li,Xiaoping Li,Fei Li,Huahui Ren,Yan Huang,Yangqing Peng,Guanglei Li,Bo Wen,Bo Dong,Ji-Yan Chen,Qing-Shan Geng,Zhi-Wei Zhang,Huanming Yang,Jian Wang,Jun Wang,Xuan Zhang,Lise Madsen,Susanne Brix,Guang Ning,Xun Xu,Xin Liu,Yong Hou,Huijue Jia,Kunlun He,Karsten Kristiansen
DOI: https://doi.org/10.1038/s41467-017-00900-1
IF: 16.6
2017-01-01
Nature Communications
Abstract:The gut microbiota has been linked to cardiovascular diseases. However, the composition and functional capacity of the gut microbiome in relation to cardiovascular diseases have not been systematically examined. Here, we perform a metagenome-wide association study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 healthy controls. The ACVD gut microbiome deviates from the healthy status by increased abundance of Enterobacteriaceae and Streptococcus spp. and, functionally, in the potential for metabolism or transport of several molecules important for cardiovascular health. Although drug treatment represents a confounding factor, ACVD status, and not current drug use, is the major distinguishing feature in this cohort. We identify common themes by comparison with gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis. Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in promoting or preventing ACVD as well as other related diseases.